Physician profile
Daniel N Berger
NPI 1669407680
$541,208.12
in general payments reported to CMS, 2019-2025
32 companies · $63K in 2025
The $63K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120K · 2020: $55K · 2021: $77K · 2022: $102K · 2023: $70K · 2024: $52K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $128K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $36K · Travel and Lodging: $15K · Food and Beverage: $6,411 · Consulting Fee: $812 · Education: $161 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $128,331.31 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $35,707.50 |
| Travel and Lodging | $14,610.71 |
| Food and Beverage | $6,410.66 |
| Consulting Fee | $811.57 |
| Education | $161.35 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $269,972.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $96,766.86 | 2019-2025 | Farxiga, Breztri |
| Dexcom, INC. | $60,263.79 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Abbott Laboratories | $46,003.08 | 2019-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Amgen INC. | $21,700.29 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21,115.57 | 2022-2023 | |
| Mannkind Corporation | $14,000.49 | 2019-2024 | Afrezza |
| Janssen Pharmaceuticals, INC | $7,369.57 | 2019-2020 | |
| Lilly USA, LLC | $1,063.97 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $1,054.25 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Sequel Med Tech, LLC | $341.72 | 2025 | Twiist |
| Medtronic, INC. | $205.21 | 2023 | Minimed 780g |
| Beta Bionics, INC. | $165.40 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tandem Diabetes Care, INC. | $155.21 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $154.94 | 2019-2025 | Omnipod |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $140.41 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $105.19 | 2019 | |
| Abbvie INC. | $102.09 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.09 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $97.68 | 2024-2025 | |
| Amarin Pharma, INC. | $61.81 | 2019-2020 | |
| Antares Pharma, INC. | $57.98 | 2025 | Xyosted |
| Medtronic Minimed, INC. | $47.23 | 2019 | |
| Ascensia Diabetes Care US INC. | $32.62 | 2019 | |
| Eisai INC. | $20.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $19.11 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.95 | 2019 | |
| Emd Serono, INC. | $17.72 | 2020 | |
| Endo Pharmaceuticals INC. | $17.55 | 2019 | |
| Ibsa Pharma INC. | $16.40 | 2019 | |
| Corcept Therapeutics | $11.37 | 2019 | |
| Cequr Corporation | $10.97 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.